Skip Navigation
 
  • Contact Us
  • Search Toggle
  • Visit us on Twitter
  • Visit us on LinkedIn
OnKure Therapeutics logo
  • About Us
    • Our Company
    • Our Team
      • Management
      • Board of Directors
  • Our Expertise
  • Pipeline & Science
    • Our Pipeline
    • PI3K
    • Publications
  • Investors
  • News
  • Careers
    • Join Our Team
    • Job Opportunities
  • Contact Us
scientist holding microscope slide
Pipeline
Scroll Down

Publications

  • December, 2024

    OKI-219

    OKl-219 enhances activity of SOC therapies and drives combination responses in pre-clinical models of Pl3KαHl047R breast cancer

  • December, 2024

    OKI-219

    Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant selective inhibitor of PI3KαH1047R, in mutant selected solid tumors including breast cancer

  • April, 2024

    OKI-219

    OKI-219 is a Brain-Penetrant PI3KαH1047R Inhibitor that has increased activity in combination with SERDs

  • December, 2023

    OKI-179

    First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

  • December, 2023

    OKI-219

    Poster: OKI-219, a PI3Kα H1047R mutant-selective inhibitor demonstrates efficacy as a single agent and drives combination responses in pre-clinical PI3Kα H1047R mutant breast models

  • October, 2023

    OKI-179

    Presentation: Novel Strategy for RAS-Pathway Targeting: Initial Results from a Phase 1b/2 Clinical Trial of the Oral HDAC Inhibitor Bocodepsin (OKI-179) Combined with Binimetinib in Patients with RAS-Pathway-Mutated Solid Tumors and NRAS-Mutated Melanoma

  • October, 2023

    OKI-179

    Poster: Novel Strategy for RAS-Pathway Targeting: Initial Results from a Phase 1b/2 Clinical Trial of the Oral HDAC Inhibitor Bocodepsin (OKI-179) Combined with Binimetinib in Patients with RAS-Pathway-Mutated Solid Tumors and NRAS-Mutated Melanoma

  • October, 2023

    OKI-219

    Discovery and characterization of OKI-219, an orally bioavailable H1047R-mutant-selective inhibitor of PI3Kα

  • October, 2023

    OKI-179

    The class I Selective, Oral HDAC inhibitor Bocodepsin Enhances the Response to MAPK Pathway Inhibitors in Multiple Tumor Types with Mutations in MAPK Pathway Signaling Proteins

  • October, 2023

    OKI-179

    Utilizing a novel HDAC inhibitor bocodepsin (OKI-179) to overcome doxorubicin resistance in triple-negative breast cancer

  • April, 2023

    CDK12

    OKI-1546 is a selective, orally bioavailable inhibitor of CDK12 that causes tumor regression in multiple preclinical cancer models

  • April, 2022

    OKI-179

    The class I-targeting, oral HDAC inhibitor OKI-179 increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma

  • March, 2022

    OKI-179

    Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

  • August, 2021

    OKI-179

    Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms

  • October, 2020

    OKI-179

    Initial results from a phase 1 trial of OKI-179, an oral Class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors

  • October, 2020

    OKI-179

    Initial Results from a Phase 1 trial of OKI-179, an Oral Class 1-selective Depsipeptide HDCA Inhibitor, in Patients with Advanced Solid Tumors

  • January, 2020

    OKI-179

    HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

  • October, 2019

    OKI-179

    OKI-179, A 1st in Class, Orally Administered HDAC Inhibitor with a Romidepsin-like Profile

  • August, 2019

    OKI-179

    Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas

  • February, 2019

    OKI-179

    Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

ONKure Therapeutics logo white

Corporate Office

6707 Winchester Circle
Suite 400
Boulder, Colorado 80301

Tel: (720) 307-2892

Contact Us

©2025 OnKure, Inc. All Rights Reserved.

  • Site Map
  • US Privacy Policy
  • EU/UK Data Privacy Policy
  • EU/UK Cookie Policy
  • Terms of Use